GoAI
Get started
iSpecimen Inc. logo

iSpecimen Inc.

ISPC

NASDAQHealthcareMedical - Diagnostics & Research

Open in GoAI

Previous close

$1.69

−$0.58 · -25.55%

Aug 21, 4:00 PM ET

ISPC company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

16

Overpriced

Momentum

17

Strong Down

Sentiment

52

Mixed

Risk resilience

26

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

iSpecimen Inc. operates a sophisticated technological platform that effectively bridges the gap between life science researchers and crucial human biological materials. Its proprietary cloud-based system empowers scientists to efficiently locate and access a vast array of biospecimens—such as biofluids, tissues, and living cells—as well as connect with potential study subjects, all sourced from a global network of healthcare providers, including hospitals, laboratories, biobanks, and blood centers. The company develops and manages iSpecimen Marketplace, an innovative online hub that strategically links medical researchers requiring access to subjects, samples, and pertinent data with organizations that hold these invaluable resources. iSpecimen's clientele primarily includes biopharmaceutical firms, in vitro diagnostics companies, and governmental and academic research institutions. The company, established in 2009, is headquartered in Lexington, Massachusetts.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
US
CEO
Katharyn Field
Listed since
Jun 17, 2021
Employees
7

Market position

Day range

Current $1.69

52-week range

Current $1.69

Open
$1.83
Previous close
$2.27
Volume
1.55M
9.57× average
Average volume
161.53K
Average daily volume
Market cap
234.68K USD
Beta
1.64
Market reference 1
50-day average
$2.3336
-27.58% below average
200-day average
$8.9614
-81.14% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-0.01×
P/B (TTM)
0.85×
P/S (TTM)
0.5×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-108.26%
Operating margin
-2020.04%
Net margin
-2449.04%

Financial health

Debt / equity
0.14×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends114%-125%-364%-603%Gross margin, FY2021: 52.86%Gross margin, FY2022: 54.27%Gross margin, FY2023: 51.45%Gross margin, FY2024: 42.93%Gross margin, FY2025: 1.25%Operating margin, FY2021: -53.21%Operating margin, FY2022: -97.92%Operating margin, FY2023: -112.50%Operating margin, FY2024: -136.99%Operating margin, FY2025: -465.42%Net margin, FY2021: -80.48%Net margin, FY2022: -98.50%Net margin, FY2023: -111.80%Net margin, FY2024: -134.51%Net margin, FY2025: -543.68%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 52.86%. Gross margin FY2022 54.27%. Gross margin FY2023 51.45%. Gross margin FY2024 42.93%. Gross margin FY2025 1.25%. Operating margin FY2021 -53.21%. Operating margin FY2022 -97.92%. Operating margin FY2023 -112.50%. Operating margin FY2024 -136.99%. Operating margin FY2025 -465.42%. Net margin FY2021 -80.48%. Net margin FY2022 -98.50%. Net margin FY2023 -111.80%. Net margin FY2024 -134.51%. Net margin FY2025 -543.68%.

Income trends

Revenue

1.93M USD-79.24%

Operating income

−8.98M USD+29.46%

Net income

−10.49M USD+16.09%
Income trends across reported periods13.52M USD3.98M USD−5.57M USD−15.11M USDRevenue, FY2021: 11.14M USDRevenue, FY2022: 10.4M USDRevenue, FY2023: 9.93M USDRevenue, FY2024: 9.29M USDRevenue, FY2025: 1.93M USDOperating income, FY2021: −5.93M USDOperating income, FY2022: −10.19M USDOperating income, FY2023: −11.17M USDOperating income, FY2024: −12.73M USDOperating income, FY2025: −8.98M USDNet income, FY2021: −8.96M USDNet income, FY2022: −10.25M USDNet income, FY2023: −11.1M USDNet income, FY2024: −12.5M USDNet income, FY2025: −10.49M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 11.14M USD. Revenue FY2022 10.4M USD. Revenue FY2023 9.93M USD. Revenue FY2024 9.29M USD. Revenue FY2025 1.93M USD. Operating income FY2021 −5.93M USD. Operating income FY2022 −10.19M USD. Operating income FY2023 −11.17M USD. Operating income FY2024 −12.73M USD. Operating income FY2025 −8.98M USD. Net income FY2021 −8.96M USD. Net income FY2022 −10.25M USD. Net income FY2023 −11.1M USD. Net income FY2024 −12.5M USD. Net income FY2025 −10.49M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1.93M USD9.29M USD9.93M USD10.4M USD11.14M USD
Cost of goods sold1.9M USD5.3M USD4.82M USD4.76M USD5.25M USD
Gross profit24.11K USD3.99M USD5.11M USD5.65M USD5.89M USD
Research and development2.16M USD3.53M USD3.57M USD2.66M USD1.84M USD
Selling, general, and administrative6.6M USD12.65M USD11.68M USD12.37M USD9.4M USD
Operating expenses9M USD16.72M USD16.28M USD15.83M USD11.81M USD
Interest income3.75K USD44.13K USD339.75K USD169.35K USD11.4K USD
Interest expense1.95K USD220.07K USD230.79K USD238.96K USD2.1M USD
Depreciation and amortization1.73M USD2.29M USD2.07M USD1.21M USD1M USD
Operating income−8.98M USD−12.73M USD−11.17M USD−10.19M USD−5.93M USD
Net income−10.49M USD−12.5M USD−11.1M USD−10.25M USD−8.96M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
67%
6 beats, 3 misses, 0 met estimates
Average EPS surprise
+33.82%
9 comparable reports
Latest EPS result
-0.98

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.36-54.95-109.54-164.13Q4 '24BeatQ2 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ2 '26BeatQ2 '26No estimateQ3 '26No estimate
Q4 2024, reported Nov 7, 2024: actual -0.84, estimate -1.52, surprise +44.74%, Beat. Q2 2025, reported Apr 14, 2025: actual -6.28, estimate -4, surprise -57.00%, Miss. Q2 2025, reported May 19, 2025: actual -0.71, estimate -4.4, surprise +83.86%, Beat. Q3 2025, reported Aug 14, 2025: actual -0.42, estimate -3.8, surprise +88.95%, Beat. Q4 2025, reported Nov 17, 2025: actual -0.48, estimate -3.8, surprise +87.37%, Beat. Q2 2026, reported Apr 1, 2026: actual -23.6, estimate -152, surprise +84.47%, Beat. Q2 2026, reported May 15, 2026: actual -6.66, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 14, 2026: actual -0.98, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates3.67M2.46M1.25M44KQ4 '24MissQ2 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ2 '26MissQ2 '26No estimateQ3 '26No estimate
Q4 2024, reported Nov 7, 2024: actual 2.66M USD, estimate 2.95M USD, surprise -9.67%, Miss. Q2 2025, reported Apr 14, 2025: actual 1.48M USD, estimate 2.98M USD, surprise -50.44%, Miss. Q2 2025, reported May 19, 2025: actual 1.06M USD, estimate 2.55M USD, surprise -58.46%, Miss. Q3 2025, reported Aug 14, 2025: actual 713.14K USD, estimate 3.1M USD, surprise -77.03%, Miss. Q4 2025, reported Nov 17, 2025: actual 106.59K USD, estimate 3.33M USD, surprise -96.80%, Miss. Q2 2026, reported Apr 1, 2026: actual 51.76K USD, estimate 3.4M USD, surprise -98.48%, Miss. Q2 2026, reported May 15, 2026: actual 156.01K USD, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 14, 2026: actual 151.94K USD, estimate —, surprise —, Comparison unavailable.

Corporate actions

Corporate action history

Stock split

Effective Apr 28, 2026

1:40

Stock split

Effective Sep 16, 2024

1:20

ISPC peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research ISPC

research.disclaimer